In Vitro Mammalian Cell Mutation Assays

Preclinical Development Handbook: Toxicology

Volumn , Issue , 2007, Pages 129-153

  Bigger, H ^a   Moore, Martha M ^b   Heflich, Robert H ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

Hypoxanthine guanine phosphoribosyl transferase gene (Hprt); Mammalian cell mutation assays; Micronucleus (MN) assays

Indexed keywords

EID: 66149136664     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249055.ch5     Document Type: Chapter

References (67)

1. Moore MM, DeMarini DM, DeSerres FJ, Tindall KR, Eds. Banbury Report 28:Mammalian Cell Mutagenesis. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory;1987.
2. Chu EHY, Malling HV. Mammalian cell genetics. II. Chemical induction of specific locus mutations in Chinese hamster cells in vitro. Proc Natl Acad Sci USA 1968;61:1306-1312.
3. Liber HL, Thilly WG. Mutation assay at the thymidine kinase locus in diploid human lymphoblasts. Mutat Res 1982;94:467-485.
4. Moore MM, Harrington-Brock K, Doerr CL, Dearfield KL. Differential mutant quantitation at the mouse lymphoma TK and CHO HGPRT loci. Mutagenesis 1989;4:394-403.
5. Aaron CS, Stankowski LF Jr. Comparison of the AS52/XPRT and the CHO/HPRT assays:evaluation of six drug candidates. Mutat Res 1989;223:121-128.
6. Aaron CS, Bolcsfoldi G, Glatt HR, Moore M, Nishi Y, Stankowski L, Theiss J, Thompson E. Mammalian cell gene mutation assays working group report. Report of the International Workshop on Standardisation of Genotoxicity Test Procedures. Mutat Res 1994;312:235-239.
7. Applegate ML, Moore MM, Broder CB, Burrell A, Juhn G, Kasweck KL, Lin P, Wadhams A, Hozier JC. Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc Natl Acad Sci USA 1990;87:51-55.
8. -/- mouse lymphoma mutagenesis assay system. Mutat Res 1981;84:169-181.
9. +/- mouse lymphoma cells. Mutat Res 1985;151:161-174.
10. +/- mouse lymphoma cell line. Mutat Res 1989;214:181-193.
11. +/- 3.7.2C mouse lymphoma cell line. Mutat Res 1985;147:243-253.
12. ICH Guidance for Industry S2B:Genotoxicity:A standard battery for genotoxicity testing of pharmacuticals(July 1997). Federal Register, 62 FR 62472(http://www.fda.gov/cder/guidance/index.htm).
13. ICH Guideline for Industry S2A:Specific aspects of regulatory genotoxicity tests for pharmaceuticals(April 1996). Federal Register, 61 FR 18199(http://www.fda.gov/cder/guidance/index.htm).
14. Dearfield KL, Auletta AE, Cimino MC, Moore MM. Considerations in the U.S. Environmental Protection Agency's testing approach for mutagenicity. Mutat Res 1991;258:259-283.
15. Müller L, Kikuchi Y, Probst G, Schechtman L, Shimada H, Sofuni T, Tweats D. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals:evolution, reasoning and impact. Mutat Res 1999;436:195-225.
16. Moore MM(Chair), Honma M(Co-Chair), Clements J(Rapporteur), Awogi T, B olcsfoldi G, Cole J, Gollapudi B, Harrington-Brock K, Mitchell A, Muster W, Myhr B, O'Donovan M, Ouldelhkim M-C, San R, Shimada H, Stankowski LF Jr. The mouse lymphoma thymidine kinase locus(tk) gene mutation assay:International Workshop on Genotoxicity Test Procedures(IWGTP) Workgroup Report. Environ Mol Mutagen 2000;35:185-190.
17. ICH M3 Guidance for Industry:Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals(July 1997). Federal Register, 62 FR 62922(http://www.fda.gov/cder/guidance/index.htm).
18. ICH S1B Guidance for Industry:Testing for carcinogenicity of pharmaceuticals(July 1997). Federal Register, 63 FR 8983(http://www.fda.gov/cder/guidance/index.htm).
19. ICH Q3A Guidance for Industry:Impurities in new drug substances(February 2003). (http://www.fda.gov/cder/guidance/index.htm).
20. ICH Q3B(R2) Guidance for Industry:Impurities in new drug products(July 2006). (http://www.fda.gov/cder/guidance/index.htm).
21. FDA CDER Guidance for Industry and Review Staff:Recommended approaches to integration of genetic toxicology study results(January 2006).(http://www.fda.gov/cder/guidance/index.htm).
22. OECD Guideline for the testing of chemicals:In vitro mammalian cell gene mutation test. OECD Guideline 476, July 1997.
23. EPA Health effects test guidelines OPPTS 870. 5300:In vitro mammalian cell gene mutation test. EPA Guideline 870.5300, August 1998.
24. Moore MM, Honma M, Clements J, Harrington-Brock K, Awogi T, Bolcsfoldi G, Cifone M, Collard D, Fellows M, Flanders K, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Kraycer J, McEnaney S, Muster W, Myhr B, O'Donovan M, Oliver J, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Shimada H, Stankowski L Jr. Mouse lymphoma thymidine kinase gene mutation assay:follow-up International Workshop on genotoxicity test procedures, New Orleans, Louisiana, April 2000. Environ Mol Mutagen 2002;40:292-299.
25. Moore MM, Honma M, Clements J, Bolcsfoldi G, Cifone M, Delongchamp R, Fellows M, Gollapudi B, Jenkinson P, Kirby P, Kirchner S, Muster W, Myhr B, O'Donovan M, Ouldelhkim M-C, Pant K, Preston R, Riach C, San R, Stankowski L Jr, Thakur A, Wakuri S, Yoshimura I. Mouse lymphoma thymidine kinase locus gene mutation assay:International Workshop(Plymouth, England) on genotoxicity test procedures workgroup report. Mutat Res 2003;540:127-140.
26. Moore MM, Honma M, Clements J, Bolcsfoldi G, Burlinson B, Cifone M, Clarke J, Delongchamp R, Durward R, Fellows M, Gollapudi B, Hou S, Jenkinson P, Lloyd M, Majeska B, Myhr B, Omori T, Riach C, San R, Stankowski L Jr, Thakur A, Van Goethem F, Wakuri S, Yoshimura I. Mouse lymphoma thymidine kinase gene mutation assay:follow-up meeting of the International Workshop on genotoxicity tests-Aberdeen, Scotland, 2003-Assay acceptance criteria, positive controls, and data evaluation. Environ Mol Mutagen 2006;47:1-5.
27. Moore MM, Honma M, Clements J, Bolcsfoldi G, Burlinson B, Cifone M, Clarke J, Clay P, Doppalapudi R, Fellows M, Gollapudi B, Hou S, Jenkinson P, Muster W, Pant K, Kidd D, Lorge E, Lloyd M, Myhr B, O'Donovan M, Riach C, Stankowski L Jr, Thakur A, Van Goethem F. Mouse lymphoma thymidine kinase gene mutation assay:meeting of the International Workshop on Genotoxicity Testing-San Francisco 2005-Recommendations for 24-h treatment. Mutat Res, 2007;627:36-40.
28. FDA CFSAN Redbook 2000:IV.C.1.c. Mouse lymphoma thymidine kinase gene mutation assay. http://www.cfsan.fda.gov/guidance.html.
29. -/- mouse lymphoma assay. In Kilbey BJ, Legator M, Nichols W, Ramel C, Eds. Handbook of Mutagenicity Test Procedures, 2nd eds. Amsterdam:Elsevier;1984, pp 239-268.
30. Cole J, Arlett CF, Green MHL, Lowe J, Muriel W. A comparison of the agar cloning and microtitration techniques for assaying cell survival and mutation frequency in L5178Y mouse lymphoma cells. Mutat Res 1983;111:371-386.
31. +/- 3.7.2C) mouse lymphoma cells. Mutagenesis 1986;1:157-167.
32. +/- 3.7.2C mouse-lymphoma cell line. Mutat Res 1982;105:451-456.
33. -/- mutants early in their clonal history. Mutat Res 1985;147:237-242.
34. +/--3.7.2C mouse lymphoma cells. Mutagenesis 1990;5:609-614.
35. Tindall KR, Stankowski LF Jr, Machanoff R, Hsie AW. Detection of deletion mutations in pSV2 gpt-transformed cells. Mol Cell Biol 1984;4:1411-1415.
36. Michaelis KC, Helvering LM, Kindig DE, Garriott ML, Richardson KK. Localization of the xanthine guanine phosphoribosyl transferase gene(gpt) of E. coli in AS52 metaphase cells by fluorescence in situ hybridization. Environ Mol Mutagen 1994;24:176-180.
37. Stankowski LF Jr, Tindall KR. Characterization of the AS52 cell line for use in mammalian cell mutagenesis studies. In Moore MM, DeMarini DM, DeSerres FJ, Tindall KR, Eds. Banbury Report 28. Cold Spring Harbor, NY:Cold Spring Harbor Laboratory;1987, pp 71-79.
38. Hsie AW, Xu ZD, Yu YJ, Sognier MA, Hrelia P. Molecular analysis of reactive oxygen-species-induced mammalian gene mutation. Teratog Carcinog Mutagen 1990;10:115-124.
39. Hsie AW, Xu Z, Yu Y, An J, Meltz ML, Schwartz JL, Hrelia P. Quantitative and molecular analyses of genetic risk:a study with ionizing radiation. Environ Health Perspect 1993;101(Suppl 3):213-218.
40. Li AP, Aaron CS, Auletta AE, Dearfield KL, Riddle JC, Slesinski RS, Stankowski LF Jr. An evaluation of the roles of mammalian cell mutation assays in the testing of chemical genotoxicity. Regul Toxicol Pharmacol 1991;14:24-40.
41. Oberly TJ, Huffman DM, Scheuring JC, Garriott ML. An evaluation of 6 chromosomal mutagens in the AS52/XPRT mutation assay utilizing suspension culture and soft agar cloning. Mutat Res 1993;319:179-187.
42. Bigger CAH, Ponten I, Page JE, Dipple A. Mutational spectra of polycyclic aromatic hydrocarbons. Mutat Res 2000;450:75-93.
43. Tennant RW, Margolin BH, Shelby MD, Zeiger E, Haseman JK, Spalding J, Caspary W, Resnick M, Stasiewicz S, Anderson B, Minor R. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 1987;236:933-941.
44. Kirkland D, Aardema M, Henderson L, Müller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 2005;584:1-256.
45. Kirkland D, Aardema M, Müller L, Hayashi M. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat Res 2006;608:29-42.
46. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data:I. Identification of carcinogens using surrogate endpoints. Regul Toxicol Pharmacol 2006;44:83-96.
47. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data:II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul Toxicol Pharmacol 2006;44:97-110.
48. +/- mouse lymphoma specific gene and chromosomal mutation assay:a phase III report of the US Environmental Protection Agency Gene-Tox Program. Mutat Res 1997;394:177-303.
49. +/- mouse lymphoma mutagen assay system. Mutat Res 1979;59:61-108.
50. Dearfield KL, Moore MM. Use of genetic toxicology information for risk assessment. Environ Mol Mutagen 2005;46:236-245.
51. Clive D, Caspary W, Kirby PE, Krehl R, Moore M, Mayo J, Oberly TJ. Guide for performing the mouse lymphoma assay for mammalian cell mutagenicity. Mutat Res 1987;189:143-156.
52. +/- mouse lymphoma cells. Mutat Res 1981;85:363-378.
53. Hsie AW, Casciano DA, Couch DB, Krahn DF, O'Neill JP, Whitfield BL. The use of Chinese hamster ovary cells to quantify specific locus mutation and to determine mutagenicity of chemicals. A report of the Gene-Tox Program. Mutat Res 1981;86:193-214.
54. Li AP, Carver JH, Choy WN, Hsie AW, Gupta RS, Loveday KS, O'Neill JP, Riddle JC, Stankowski LF Jr, Yang LL. A guide for the performance of the Chinese hamster ovary cell/hypoxanthine-guanine phosphoribosyl transferase gene mutation assay. Mutat Res 1987;189:135-141.
55. Stankowski LF Jr, Tindall KR, Hsie AW. Quantitative and molecular analyses of ethyl methanesulfonate-and ICR 191-induced mutation in AS52 cells. Mutat Res 1986;160:133-147.
56. Chen T, Moore MM. Screening for chemical mutagens using the mouse lymphoma assay. In Yan Z, Caldwell GW, Eds. Methods in Pharmacology and Toxicology Optimization in Drug Discovery:In Vitro Methods. Totowa, NJ:Humana Press;2004, pp 337-352.
57. +/--3.7.2C mouse lymphoma cell line. Environ Mol Mutagen 2006;47:127-131.
58. Brock KH, Moore MM, Oglesby LA. Development of an intact hepatocyte activation system for routine use with the mouse lymphoma assay. Environ Mutagen 1987;9:331-341.
59. Oglesby LA, Harrington-Brock K, Moore MM. Induced hepatocytes as a metabolic activation system for the mouse-lymphoma assay. Mutat Res 1989;223:295-302.
60. +/- mouse lymphoma cells at varying times post treatment. Environ Mutagen 1982;4:499-519.
61. Robison WD, Green MHL, Cole J, Healy MJR, Garner RC, Gatehouse D. Statistical evaluation of bacterial/mammalian fluctuation tests. In Kirkland DJ, Ed. Statistical Evaluation of Mutagenicity Test Data. Cambridge, UK:Cambridge University Press;1989, pp 102-140.
62. Hsie AW, Brimer PA, Mitchell TJ, Gosslee DG. The dose-response relationship for ethyl methanesulfonate-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells. Somatic Cell Genet 1975;1:247-261.
63. Machanoff R, O'Neill JP, Hsie AW. Quantitative analysis of cytotoxicity and mutagenicity of benzo[ a ]pyrene in mammalian cells(CHO/HGPRT system). Chem-Biol Interact 1981;34:1-10.
64. Li AP, Gupta RS, Heflich RH, Wassom JS. A review and analysis of the Chinese hamster ovary/hypoxanthine guanine phosphoribosyl transferase assay to determine the mutagenicity of chemical agents; a report of Phase III of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 1988;196:17-36.
65. Putman DL, San RHC, Bigger CAH, Jacobson-Kram D. Genetic toxicology. In Derelanko MJ, Hollinger MA, Eds. CRC Handbook of Toxicology. New York:CRC Press;1995, pp 337-355.
66. Tindall KR, Stankowski LF Jr, Machanoff R, Hsie AW. Analysis of mutation in PSV2 gpt-transformed CHO cells. Mutat Res 1986;160:121-131.
67. Li AP. Spontaneous frequency of 6-thioguanine resistant mutants in CHO-AS52 cells after prolonged culturing in the absence of selective agents. Environ Mol Mutagen 1990;15:214-217.